YU91802A - Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijata - Google Patents

Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijata

Info

Publication number
YU91802A
YU91802A YU91802A YUP91802A YU91802A YU 91802 A YU91802 A YU 91802A YU 91802 A YU91802 A YU 91802A YU P91802 A YUP91802 A YU P91802A YU 91802 A YU91802 A YU 91802A
Authority
YU
Yugoslavia
Prior art keywords
azabicyclo
opiate
pharmaceutically
opioid receptor
useful
Prior art date
Application number
YU91802A
Other languages
English (en)
Inventor
Bernard Joseph Banks
Douglas James Critcher
Ashley Edward Fenwick
David Morris Gethin
Graham Lunn
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU91802A publication Critical patent/YU91802A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Jedinjenja formule (I) gde su supstituenti definisani u opisu, i njegovi farmaceutski ili veterinarski prihvatljivi derivati, korisni su farmaceutski i veterinarski, naročito zato što se vežu za receptore opijata (npr. mi, kapa i delta receptore opijata). Oni su pogodni za upotrebu u tretmanu bolesti ili stanja posredovanih receptorima opijata, kao što su na primer sindrom iritabilne utrobe; konstipacija; mučnina; povraćanje; prirutičke dermatoze, kao što su alergijski dermatitis i atopija; poremećaji u ishrani; prekomerno uzimanje opijata; depresija; zavisnost od pušenja i alkohola; seksualna disfunkcija; šok; šlog; povreda kičme; i trauma glave.[Compounds of formula (I), where the substituents are as defined herein, and the pharmaceutically or veterinarily acceptable derivatives or prodrugs thereof, are pharmaceutically and veterinarily useful, in particular they bind to opiate receptors (e.g. mu, kappa and delta opioid receptors). They are likely to be useful in the treatment of diseases or conditions modulated by opiate receptors, for example irritable bowel syndrome; constipation; nausea; vomiting; pruritic dermatoses, such as allergic dermatitis and atopy; eating disorders; opiate overdoses; depression; smoking and alcohol addiction; sexual dysfunction; shock; stroke; spinal damage; and head trauma.
YU91802A 2000-06-23 2001-06-07 Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijata YU91802A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0015562.2A GB0015562D0 (en) 2000-06-23 2000-06-23 Heterocycles

Publications (1)

Publication Number Publication Date
YU91802A true YU91802A (sh) 2006-05-25

Family

ID=9894368

Family Applications (1)

Application Number Title Priority Date Filing Date
YU91802A YU91802A (sh) 2000-06-23 2001-06-07 Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijata

Country Status (34)

Country Link
EP (1) EP1292574A1 (sh)
JP (1) JP2004512263A (sh)
KR (1) KR20040002386A (sh)
CN (1) CN1639121A (sh)
AP (1) AP2002002698A0 (sh)
AR (1) AR028969A1 (sh)
AU (1) AU781837B2 (sh)
BG (1) BG107329A (sh)
BR (1) BR0111867A (sh)
CA (1) CA2412188A1 (sh)
CZ (1) CZ20023967A3 (sh)
DO (1) DOP2001000187A (sh)
DZ (1) DZ3368A1 (sh)
EA (1) EA005117B1 (sh)
GB (1) GB0015562D0 (sh)
HR (1) HRP20020998A2 (sh)
HU (1) HUP0301228A3 (sh)
IL (1) IL153427A0 (sh)
IS (1) IS6637A (sh)
MA (1) MA26915A1 (sh)
MX (1) MXPA02012878A (sh)
NO (1) NO20026168L (sh)
NZ (1) NZ523141A (sh)
OA (1) OA12293A (sh)
PA (1) PA8519401A1 (sh)
PE (1) PE20020253A1 (sh)
PL (1) PL365956A1 (sh)
SK (1) SK17172002A3 (sh)
TN (1) TNSN01094A1 (sh)
UA (1) UA73176C2 (sh)
UY (1) UY26787A1 (sh)
WO (1) WO2001098267A1 (sh)
YU (1) YU91802A (sh)
ZA (1) ZA200210278B (sh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213464A (pt) 2001-10-22 2004-11-09 Pfizer Prod Inc Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
EP2074997A1 (en) * 2002-05-17 2009-07-01 Tioga Pharmaceuticals, Inc. Use of Asimadoline for the treatment of digestive disorders
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
DK1745040T3 (da) 2004-02-23 2010-04-12 Glaxo Group Ltd Som modulatorer af dopamin-D3-receptorer anvendelige azabicyclo(3.1.0)hexanederivater
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
JP5068747B2 (ja) * 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンd3受容体のモジュレーターとしてのアザビシクロ[3.1.0]ヘキサン誘導体
WO2007113258A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
EP2561870A1 (en) 2007-03-30 2013-02-27 Tioga Pharmaceuticals, Inc. Kappa-Opiate Agonists For The Treatment Of Diarrhea-Predominant and Alternating Irritable Bowel Syndrome
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之8-氮雜雙環〔3.2.1〕辛基-2-羥基苯甲醯胺化合物
AU2011263417B2 (en) 2010-06-11 2014-03-27 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
WO2012042539A2 (en) 2010-09-28 2012-04-05 Panacea Biotec Ltd Novel bicyclic compounds
KR102305244B1 (ko) * 2013-11-20 2021-09-27 우베 고산 가부시키가이샤 신규 3-아자비사이클로[3.1.0]헥산 유도체 및 그 의약 용도
JP6087035B1 (ja) 2015-05-20 2017-03-01 株式会社三和化学研究所 新規3−アザビシクロ[3.1.0]ヘキサン誘導体の塩の結晶及びその医薬用途
BR112019016827A2 (pt) * 2017-02-17 2020-04-07 Trevena Inc compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
AU2018229062A1 (en) 2017-03-02 2019-09-26 Ube Industries, Ltd. Therapeutic agent for alcohol use disorders
CN108250088B (zh) * 2018-01-04 2020-10-30 四川之江高新材料股份有限公司 N,n,n′-三甲基-n′-羟乙基双氨基乙基醚的制备方法
CN115825305B (zh) * 2022-10-21 2024-09-20 昆明理工大学 一种分子印迹固相微萃取纤维及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
ES2058265T3 (es) * 1987-04-16 1994-11-01 Lilly Co Eli Piperidinas antagonistas de opiaceos.
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5

Also Published As

Publication number Publication date
AR028969A1 (es) 2003-05-28
BG107329A (en) 2003-07-31
HUP0301228A2 (hu) 2003-08-28
HUP0301228A3 (en) 2005-08-29
PL365956A1 (en) 2005-01-24
IS6637A (is) 2002-11-28
UY26787A1 (es) 2002-01-31
EA200201269A1 (ru) 2003-06-26
DZ3368A1 (fr) 2001-12-27
PE20020253A1 (es) 2002-04-08
IL153427A0 (en) 2003-07-06
SK17172002A3 (sk) 2004-09-08
AU6259101A (en) 2002-01-02
BR0111867A (pt) 2003-07-01
NO20026168L (no) 2003-02-18
MXPA02012878A (es) 2003-05-14
ZA200210278B (en) 2003-12-19
EA005117B1 (ru) 2004-10-28
AP2002002698A0 (en) 2002-12-31
HRP20020998A2 (en) 2004-02-29
PA8519401A1 (es) 2002-12-30
DOP2001000187A (es) 2002-03-30
WO2001098267A1 (en) 2001-12-27
OA12293A (en) 2004-03-18
NZ523141A (en) 2005-06-24
EP1292574A1 (en) 2003-03-19
CZ20023967A3 (cs) 2004-02-18
GB0015562D0 (en) 2000-08-16
KR20040002386A (ko) 2004-01-07
UA73176C2 (en) 2005-06-15
WO2001098267A8 (en) 2003-02-27
MA26915A1 (fr) 2004-12-20
JP2004512263A (ja) 2004-04-22
CN1639121A (zh) 2005-07-13
TNSN01094A1 (fr) 2005-11-10
CA2412188A1 (en) 2001-12-27
NO20026168D0 (no) 2002-12-20
AU781837B2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
YU91802A (sh) Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijata
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
TW200503713A (en) Novel compounds
UA84930C2 (ru) Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
TW200505921A (en) Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2002036596A3 (en) CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
WO2007078523A3 (en) 5-phenyl-3-benzyl-0xaz0lidin-2-0ne derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders
WO2006116218A8 (en) Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2009125923A3 (en) Novel indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
MX2007005611A (es) Compuestos de imidazo[1,2-a]piridina, composiciones, usos y metodos relacionados.
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
MA29623B1 (fr) Derives de pyrazolo [3, 4-d] azepine comme antagonistes d'histamine h3
GEP20043366B (en) Benzothiophene Derivative Compounds Process of Preparation and Use Thereof
DE602004024188D1 (de) Des opioid-rezeptors
TW200514781A (en) Novel compounds
WO2004089908A3 (en) 3-azabicyclo[3.2.1]octane derivatives
WO2005110409A3 (en) Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity
HK1127899A1 (en) Process for the synthesis of (+) and (-) -1-(3,4-dichlorophenyl)-3- azabicyclo[3.1.0]hexane
WO2005035504A3 (en) 5-h -benzo [d] naphth [2, 1-b] azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders